Divi's Laboratories (DIVISLAB) Aperçu de l'action
Divi's Laboratories Limited fabrique et vend des ingrédients pharmaceutiques actifs (IPA) génériques, des produits intermédiaires et des nutraceutiques en Inde, en Amérique du Nord, en Asie, en Europe et dans le monde entier. Plus de détails
| Score flocon de neige | |
|---|---|
| Évaluation | 0/6 |
| Croissance future | 3/6 |
| Performances passées | 4/6 |
| Santé financière | 5/6 |
| Dividendes | 4/6 |
DIVISLAB Community Fair Values
Create NarrativeSee what 18 others think this stock is worth. Follow their fair value or set your own to get alerts.
Analyst Price Targets
ST
stuart_roberts
Community ContributorUS$21.53FV • 64.4% sous-évalué décote intrinsèque
5419.8%Revenue growth p.a.
6.2k
18
0
126
Divi's Laboratories Limited Concurrents
Historique des prix et performances
| Historique des cours de bourse | |
|---|---|
| Prix actuel de l'action | ₹6,502.50 |
| Plus haut sur 52 semaines | ₹7,071.50 |
| Plus bas sur 52 semaines | ₹5,636.50 |
| Bêta | 0.19 |
| Variation sur 1 mois | 9.34% |
| Variation sur 3 mois | 7.46% |
| Variation sur 1 an | 6.83% |
| Variation sur 3 ans | 98.09% |
| Variation sur 5 ans | 60.04% |
| Évolution depuis l'introduction en bourse | 73,687.23% |
Nouvelles et mises à jour récentes
DIVISLAB: Upcoming Board Review Will Support Bullish Long Term Outlook
Analysts have lifted their price target for Divi's Laboratories slightly, with fair value now seen around ₹8,620 versus about ₹8,554 earlier, reflecting updated assumptions for discount rate, revenue growth, profit margin and future P/E. What's in the News A board meeting is scheduled on Feb 11, 2026 to consider and approve unaudited standalone financial results for the quarter and nine months ended Dec 31, 2025 (Key Developments).
DIVISLAB: Elevated Future P/E Will Persist Despite Unchanged Fair Value Estimate
Analysts have maintained Divi's Laboratories' fair value estimate at ₹5,140 per share, with only small tweaks to assumptions such as discount rate, revenue growth, profit margin, and future P/E, which together guide the latest price target narrative. What's in the News Board meeting scheduled for February 11, 2026, to review and approve unaudited standalone financial results for the quarter and nine months ended December 31, 2025 (Key Developments).
DIVISLAB: Upcoming Board Review And Fair Value Update Signal Constructive Outlook
Analysts have made a small upward adjustment to the fair value estimate for Divi's Laboratories to around ₹6,875, reflecting slightly updated assumptions on the discount rate, revenue growth, profit margins and future P/E. What's in the News Board meeting scheduled on February 11, 2026, to review and approve unaudited standalone financial results for the quarter and nine months ended December 31, 2025 (company filing).DIVISLAB: Rich Future P/E Will Persist Despite Softer Outlook After Results
Analysts have trimmed their price target on Divi's Laboratories from ₹5,290 to ₹5,140, reflecting updated assumptions around a slightly lower revenue growth outlook, a marginally higher profit margin, a modestly reduced future P/E multiple, and an adjusted discount rate. What's in the News A board meeting is scheduled for February 11, 2026 to review and approve unaudited standalone and consolidated financial results for the quarter ended December 31, 2025 (Key Developments).DIVISLAB: Upcoming Results Review Will Shape Balanced Long Term Outlook
Narrative Update on Divi's Laboratories The analyst price target for Divi's Laboratories has been adjusted slightly higher from about ₹6,823 to roughly ₹6,870, with analysts pointing to small refinements in assumptions around discount rate, revenue growth, profit margin and future P/E as the drivers of this change. What's in the News A board meeting is scheduled for February 11, 2026, to review and approve unaudited standalone financial results for the quarter and nine months ended December 31, 2025 (company filing).Recent updates
DIVISLAB: Upcoming Board Review Will Support Bullish Long Term Outlook
Analysts have lifted their price target for Divi's Laboratories slightly, with fair value now seen around ₹8,620 versus about ₹8,554 earlier, reflecting updated assumptions for discount rate, revenue growth, profit margin and future P/E. What's in the News A board meeting is scheduled on Feb 11, 2026 to consider and approve unaudited standalone financial results for the quarter and nine months ended Dec 31, 2025 (Key Developments).DIVISLAB: Elevated Future P/E Will Persist Despite Unchanged Fair Value Estimate
Analysts have maintained Divi's Laboratories' fair value estimate at ₹5,140 per share, with only small tweaks to assumptions such as discount rate, revenue growth, profit margin, and future P/E, which together guide the latest price target narrative. What's in the News Board meeting scheduled for February 11, 2026, to review and approve unaudited standalone financial results for the quarter and nine months ended December 31, 2025 (Key Developments).DIVISLAB: Upcoming Board Review And Fair Value Update Signal Constructive Outlook
Analysts have made a small upward adjustment to the fair value estimate for Divi's Laboratories to around ₹6,875, reflecting slightly updated assumptions on the discount rate, revenue growth, profit margins and future P/E. What's in the News Board meeting scheduled on February 11, 2026, to review and approve unaudited standalone financial results for the quarter and nine months ended December 31, 2025 (company filing).DIVISLAB: Rich Future P/E Will Persist Despite Softer Outlook After Results
Analysts have trimmed their price target on Divi's Laboratories from ₹5,290 to ₹5,140, reflecting updated assumptions around a slightly lower revenue growth outlook, a marginally higher profit margin, a modestly reduced future P/E multiple, and an adjusted discount rate. What's in the News A board meeting is scheduled for February 11, 2026 to review and approve unaudited standalone and consolidated financial results for the quarter ended December 31, 2025 (Key Developments).DIVISLAB: Upcoming Results Review Will Shape Balanced Long Term Outlook
Narrative Update on Divi's Laboratories The analyst price target for Divi's Laboratories has been adjusted slightly higher from about ₹6,823 to roughly ₹6,870, with analysts pointing to small refinements in assumptions around discount rate, revenue growth, profit margin and future P/E as the drivers of this change. What's in the News A board meeting is scheduled for February 11, 2026, to review and approve unaudited standalone financial results for the quarter and nine months ended December 31, 2025 (company filing).DIVISLAB: Upcoming Results Review Will Support Bullish Long Term Outlook
Analysts have lifted their price target on Divi's Laboratories slightly to ₹6,823 from about ₹6,785, citing refreshed assumptions around discount rates, revenue growth, profit margin and future P/E that remain broadly in line with prior views. What's in the News A board meeting is scheduled for February 11, 2026, to review and approve unaudited standalone and consolidated financial results for the quarter and nine months ended December 31, 2025 (Key Developments).DIVISLAB: Management Changes And Rich Future P/E Will Sustain Excessive Optimism
Analysts now cite slightly higher assumptions on growth, profitability and future P/E in their models for Divi's Laboratories, which feeds into an updated fair value estimate of ₹5,290, compared with the previous ₹5,035.89. What's in the News Board meeting scheduled for November 7, 2025, at 10:30 Indian Standard Time to review unaudited standalone and consolidated financial results for the quarter and half year ended September 30, 2025 (company filing).DIVISLAB: Upcoming Board Review And Management Changes Will Support Bullish Outlook
Analysts have raised their price target for Divi's Laboratories from ₹7,750 to about ₹8,554, citing updated assumptions related to revenue growth, profit margins and future P/E levels in their models. What's in the News Board meeting scheduled on Nov 07, 2025 at 10:30 Indian Standard Time to review unaudited standalone and consolidated financial results for the quarter and half year ended Sep 30, 2025 (company filing).Earnings Not Telling The Story For Divi's Laboratories Limited (NSE:DIVISLAB)
Dec 30
DIVISLAB: Rising Profitability Expectations Will Mask Moderating Revenue And Justify Excessive Optimism
Analysts have raised their price target for Divi's Laboratories from ₹4,756 to ₹5,036, citing expectations of stronger profitability and a slightly richer future valuation multiple, despite moderating revenue growth assumptions. What's in the News Board meeting scheduled for November 7, 2025 at 10:30 Indian Standard Time to review unaudited standalone and consolidated financial results for the quarter and half year ended September 30, 2025 (company filing).DIVISLAB: Upcoming Board Meeting And Leadership Review Will Shape Fair Outlook
Analysts have nudged their price target for Divi's Laboratories slightly higher, reflecting marginal improvements in discount rate assumptions and long term growth expectations that together support a fair value estimate of ₹6,785.10 per share. What's in the News Board meeting scheduled for November 7, 2025, at 10:30 IST to review unaudited standalone and consolidated financial results for the quarter and half year ended September 30, 2025 (company filing).Divi's Laboratories (NSE:DIVISLAB) Seems To Use Debt Quite Sensibly
Dec 09DIVISLAB: Upcoming Board Decisions And Modest Earnings Improvements Will Shape Outlook
Analysts have raised their fair value estimate for Divi's Laboratories from ₹6,433 to ₹6,785, citing modest improvements in revenue growth and profit margin expectations. What's in the News A board meeting is scheduled for November 7, 2025, at 10:30 IST to consider and approve unaudited standalone and consolidated financial results for the quarter and half year ended September 30, 2025 (Key Developments).Investors Shouldn't Be Too Comfortable With Divi's Laboratories' (NSE:DIVISLAB) Earnings
Nov 15Divi's Laboratories Limited Just Beat Earnings Expectations: Here's What Analysts Think Will Happen Next
Nov 11DIVISLAB: Upcoming Board Decisions And Modest Earnings Improvements Will Shape Outlook
Analysts have modestly increased their price target for Divi's Laboratories from ₹6,363 to ₹6,433, citing slight improvements in projected revenue growth and profit margins as the underlying factors. What's in the News Upcoming Board Meeting scheduled for November 7, 2025, at 10:30 AM IST.Divi's Laboratories Limited's (NSE:DIVISLAB) Share Price Could Signal Some Risk
Sep 06Custom Synthesis And Capacity Expansion Will Unlock Global Demand
With both the consensus price target and future P/E ratio for Divi's Laboratories remaining virtually unchanged, analysts signal stable valuation expectations, resulting in a steady fair value assessment at ₹6363. What's in the News Board meeting scheduled to consider and approve unaudited standalone and consolidated financial results for the quarter ended June 30, 2025.Divi's Laboratories Limited Earnings Missed Analyst Estimates: Here's What Analysts Are Forecasting Now
Aug 10Most Shareholders Will Probably Agree With Divi's Laboratories Limited's (NSE:DIVISLAB) CEO Compensation
Aug 05Here's What Analysts Are Forecasting For Divi's Laboratories Limited (NSE:DIVISLAB) After Its Yearly Results
Jul 17
Tactical Expansions And Innovation Could Offset Generic Pricing Pressures And Boost Profitability
Strategic investments in peptide synthesis and greenfield expansion enhance future revenue potential through capacity and product line growth.Rendement pour les actionnaires
| DIVISLAB | IN Life Sciences | IN Marché | |
|---|---|---|---|
| 7D | 1.9% | 2.2% | -0.7% |
| 1Y | 6.8% | 4.8% | 3.9% |
Rendement vs Industrie: DIVISLAB a dépassé le secteur Indian Life Sciences qui a rapporté 4.8 % au cours de l'année écoulée.
Rendement vs marché: DIVISLAB a dépassé le marché Indian qui a rapporté 3.9 % au cours de l'année écoulée.
Volatilité des prix
| DIVISLAB volatility | |
|---|---|
| DIVISLAB Average Weekly Movement | 3.3% |
| Life Sciences Industry Average Movement | 6.3% |
| Market Average Movement | 7.2% |
| 10% most volatile stocks in IN Market | 10.2% |
| 10% least volatile stocks in IN Market | 4.7% |
Cours de l'action stable: DIVISLAB n'a pas connu de volatilité de prix significative au cours des 3 derniers mois par rapport au marché Indian.
Volatilité au fil du temps: La volatilité hebdomadaire de DIVISLAB ( 3% ) est restée stable au cours de l'année écoulée.
À propos de l'entreprise
| Fondée | Salariés | PDG | Site web |
|---|---|---|---|
| 1990 | 10,542 | Kiran Divi | www.divislabs.com |
Divi's Laboratories Limited fabrique et vend des ingrédients pharmaceutiques actifs (IPA) génériques, des produits intermédiaires et des nutraceutiques en Inde, en Amérique du Nord, en Asie, en Europe et dans le monde entier. L'entreprise propose également des services de synthèse à façon pour la fabrication d'IPA et de produits intermédiaires, et fournit une gamme de caroténoïdes, tels que le bêta-carotène, l'astaxanthine, le lycopène et la canthaxanthine, ainsi que d'autres formes finies, dont la lutéine, et des vitamines aux industries de l'alimentation humaine, des compléments alimentaires et des fabricants d'aliments pour animaux. Elle exporte également ses produits.
Divi's Laboratories Limited Résumé des fondamentaux
| DIVISLAB statistiques fondamentales | |
|---|---|
| Capitalisation boursière | ₹1.73t |
| Bénéfices(TTM) | ₹24.79b |
| Recettes(TTM) | ₹103.14b |
69.6x
Ratio P/E16.7x
Ratio P/SLe site DIVISLAB est-il surévalué ?
Voir Juste valeur et analyse de l'évaluationBénéfices et recettes
| DIVISLAB compte de résultat (TTM) | |
|---|---|
| Recettes | ₹103.14b |
| Coût des recettes | ₹39.55b |
| Marge brute | ₹63.59b |
| Autres dépenses | ₹38.80b |
| Les revenus | ₹24.79b |
Derniers bénéfices déclarés
Dec 31, 2025
Prochaine date de publication des résultats
s/o
| Résultat par action (EPS) | 93.38 |
| Marge brute | 61.65% |
| Marge bénéficiaire nette | 24.04% |
| Ratio dettes/capitaux propres | 0.6% |
Quelles ont été les performances à long terme de DIVISLAB?
Voir les performances historiques et les comparaisonsDividendes
0.5%
Rendement actuel des dividendes36%
Ratio de distributionAnalyse de l'entreprise et données financières
| Données | Dernière mise à jour (heure UTC) |
|---|---|
| Analyse de l'entreprise | 2026/04/30 05:32 |
| Cours de l'action en fin de journée | 2026/04/30 00:00 |
| Les revenus | 2025/12/31 |
| Revenus annuels | 2025/03/31 |
Sources de données
Les données utilisées dans notre analyse de l'entreprise proviennent de S&P Global Market Intelligence LLC. Les données suivantes sont utilisées dans notre modèle d'analyse pour générer ce rapport. Les données sont normalisées, ce qui peut entraîner un délai avant que la source ne soit disponible.
| Paquet | Données | Cadre temporel | Exemple de source américaine * |
|---|---|---|---|
| Finances de l'entreprise | 10 ans |
| |
| Estimations consensuelles des analystes | +3 ans |
|
|
| Prix du marché | 30 ans |
| |
| Propriété | 10 ans |
| |
| Gestion | 10 ans |
| |
| Principaux développements | 10 ans |
|
* Exemple pour les titres américains ; pour les titres non américains, des formulaires réglementaires et des sources équivalentes sont utilisés.
Sauf indication contraire, toutes les données financières sont basées sur une période annuelle mais mises à jour trimestriellement. C'est ce qu'on appelle les données des douze derniers mois (TTM) ou des douze derniers mois (LTM). En savoir plus.
Modèle d'analyse et flocon de neige
Les détails du modèle d’analyse utilisé pour générer ce rapport sont disponibles sur notre page Github; nous proposons également des guides expliquant comment utiliser nos rapports et des tutoriels sur Youtube.
Découvrez l'équipe de classe mondiale qui a conçu et construit le modèle d'analyse Simply Wall St.
Indicateurs de l'industrie et du secteur
Nos indicateurs de secteur et de section sont calculés toutes les 6 heures par Simply Wall St. Les détails de notre processus sont disponibles sur Github.
Sources des analystes
Divi's Laboratories Limited est couverte par 57 analystes. 30 de ces analystes ont soumis les estimations de revenus ou de bénéfices utilisées comme données d'entrée dans notre rapport. Les soumissions des analystes sont mises à jour tout au long de la journée.
| Analyste | Institution |
|---|---|
| Rohit Bhat | 360 ONE Capital Market Private Limited |
| Gaurav Tinani | Ambit Capital |
| Nitin Bhasin | Ambit Capital |